DNAe Appoints Richard Hammond as Vice President of Technology
London, UK and Carlsbad, CA, USA – 13 May 2021 – DNAe, the next generation sequencing company developing novel diagnostics for use at the point-of-need, has appointed Richard Hammond as Vice President of Technology.
Richard has worked for over 20 years in the field of medical device development, at the intersection of biology and engineering. He has extensive leadership and program management experience, primarily focused on developing products for regulated markets. He also has experience working for government sponsors on major programs.
He joins DNAe following six years with Cambridge Consultants where he held the positions of Technology Director and Head of Bioinnovation. The Bioinnovation team, which Richard established, built, and led, delivers technology development services at the overlap between biology, engineering, and computation.
Prior to this, Richard was Program Manager of R&D at Alere Inc. (now Abbott Rapid Diagnostics), where he led the team that developed the Abbott ID Now platform, the world’s first CLIA-Waived point-of-care molecular test for infectious disease.
Richard holds a master’s degree in Engineering from the University of Cambridge.
Commenting on Richard’s appointment, Samuel Reed, CEO of DNAe, said: “We are pleased to welcome Richard to further strengthen our fantastic team. His extensive experience, technical insight and in-depth knowledge in medical device development will be a great asset as we work to bring our LiDia-SEQ™ diagnostic platform into the clinic and to market.”
Richard Hammond commented: “It’s great to be joining DNAe at an exciting stage of the Company’s development. The team has done a wonderful job to date in developing DNAe’s proprietary semiconductor sequencing technology into an end-to-end solution for use ultimately as a diagnostic. I look forward to building on this success and us delivering LiDia-SEQ™ to clinicians and other users.”
